Peer Reviewed Publications

  1. Jaffar S JJ, Aniss A, Tsang VHM, Learoyd D, Clifton-Bligh RJ, GIll AJ, GLover AR, Sidhu SB, Robinson BG, Sywak M. Predicting Distant Metastatic Disease in Differentiated Thyroid Cancer: A Matched Case-Control Study. ANZ Journal of Surgery. 2021 (in press);ePub (In press).

  2. Gild ML, Tsang V, Clifton-Bligh RJ, Robinson BG. Multiple Endocrine Neoplasia Type 2 and Medullary Thyroid carcinoma. In: Jameson J Larry DGL, editor. Endocrinology: Adult and Paediatric: Saunders; 2021 (In press).

  3. Tsang V LS. Secondary hypertension in three vignettes. Endocrinology Today. 2021;10(1):6.

  4. Gild ML, Tsang VHM, Clifton-Bligh RJ, Robinson BG. Multikinase inhibitors in thyroid cancer: timing of targeted therapy. Nat Rev Endocrinol. 2021.

  5. Muir C C-BR, Long GV, Scolyer RA, Lo S, Tsang VHM, Menzies AM. Thyroid immune related adverse effects occurring in association with immune checkpoint inhibitor treatment. 2020 (In preparation).

  6. Wu L, Nahm CB, Jamieson NB, Samra J, Clifton-Bligh R, Mittal A, Tsang VHM. Risk factors for development of diabetes mellitus (Type 3c) after partial pancreatectomy: A systematic review. Clinical endocrinology. 2020.

  7. Tsang VHM, McGrath RT, Clifton-Bligh RJ, Scolyer RA, Jakrot V, Guminski AD, et al. Response to Letter to the Editor: "Checkpoint Inhibitor-Associated Autoimmune Diabetes is Distinct From Type 1 Diabetes". The Journal of clinical endocrinology and metabolism. 2020;105(6):e2317-8.

  8. Tsang VHM, McGrath RT, Clifton-Bligh RJ, Scolyer RA, Jakrot V, Guminski AD, et al. Response to Letter to the Editor: "Checkpoint Inhibitor-Associated Autoimmune Diabetes is Distinct From Type 1 Diabetes". The Journal of clinical endocrinology and metabolism. 2020;105(6).

  9. Tsang VH, Gild M, Glover A, Clifton-Bligh R, Robinson BG. Thyroid cancer in the age of COVID-19. Endocrine-related cancer. 2020.

  10. Nylén C, Mechera R, Maréchal-Ross I, Tsang V, Chou A, Gill AJ, et al. Molecular Markers Guiding Thyroid Cancer Management. Cancers. 2020;12(8).

  11. Muir CA, Menzies AM, Clifton-Bligh R, Tsang VHM. Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer. Thyroid. 2020.

  12. Lin M, Tsang V, Brewer J, Clifton-Bligh R, Gild ML. Infiltrative lymphocytic hypophysitis successfully treated with rituximab and mycophenolate mofetil. Endocrinol Diabetes Metab Case Rep. 2020;2020.

  13. Fuchs TL, Nassour AJ, Glover A, Sywak MS, Sidhu SB, Delbridge LW, Clifton-Bligh RJ, Gild ML, Tsang VHM Robinson BG, Clarkson A, Sheen A, SIoson L, Chou A, Gill AJ A Proposed Grading Scheme for Medullary Thyroid Carcinoma Based on Proliferative Activity (Ki-67 and Mitotic Count) and Coagulative Necrosis. The American journal of surgical pathology. 2020.

  14. Clifford L GC, Tsang VH. Amiodarone Induced Thyrotoxicosis: When It Becomes a Storm. Endocrinology Today 2020;9(4):4.

  15. Tsang VHM, McGrath RT, Clifton-Bligh RJ, Scolyer RA, Jakrot V, Guminski AD, et al. Checkpoint inhibitor associated autoimmune diabetes (CIADM) is distinct from type 1 diabetes. The Journal of clinical endocrinology and metabolism. 2019.

  16. Tsang VHM. Management of treatment-related toxicities in advanced medullary thyroid cancer. Current opinion in oncology. 2019;31(3):236-42.

  17. Tsang V CB. Endocrine immune related adverse events. Endocrinology Today. 2019.

  18. Lin M CB, Glastras S, Tsang VH. New onset hyperglycaemia in pregnancy. Endocrinology Today. 2019;8(4):5.

  19. Wijetunga A, Tsang V, Giuffre B. The Utility of Cross-Sectional Imaging in the Management of Suspected Scaphoid Fractures. Journal of Medical Radiation Sciences 2018.

  20. Scott ES, Long GV, Guminski A, Clifton-Bligh RJ, Menzies AM, Tsang VH. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. European journal of endocrinology. 2018;178(2):175-82.

  21. LAU Sue Lynn, Tsang V. Recognising and correcting hyponatraemia in an elderly woman. Endocrinology Today. 2018;7(2):5.

  22. Jang HS, Parratt JDE, Tsang VHM, Coyle LA, Fernando SL. Serum vascular endothelial growth factor (VEGF) level can be used as a diagnostic marker in POEMS syndrome. Pathology. 2018;50(6):674-6.

  23. Gild ML, Tsang V, Samra J, Clifton-Bligh RJ, Tacon L, Gill AJ. Hypercalcemia in glucagon cell hyperplasia and neoplasia (Mahvash syndrome): a new association. The Journal of clinical endocrinology and metabolism. 2018.

  24. De Sousa SMC, Sheriff N, Tran CH, Menzies AM, Tsang VHM, Long GV, et al. Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis. Pituitary. 2018.

  25. Wijewardene AA, Glastras SJ, Learoyd DL, Robinson BG, Tsang VHM. ACTH-secreting medullary thyroid cancer: a case series. Endocrinol Diabetes Metab Case Rep. 2017;2017.

  26. Sung J, Tsang V, Lau SL. Recurrent hypoglycaemia with reduced recognition. Endocrinology Today. 2017;6(4):5.

  27. Kam J, Tsang VH, Chalasani V. Retrograde Ejaculation: A Rare Presenting Symptom of Type 1 Diabetes Mellitus. Urol Case Rep. 2017;10:9-10.

  28. Bennett M LS, Tsang VH. Management of acute renal failure and hypercalcaemia. Endocrinology Today. 2017;6(1):31.

  29. Tsang VH, Robinson BG, Learoyd DL. The safety of vandetanib for the treatment of thyroid cancer. Expert Opin Drug Saf. 2016;15(8):1107-13.

  30. Logaraj A, Tsang VH, Kabir S, Ip JC. Adrenal crisis secondary to bilateral adrenal haemorrhage after hemicolectomy. Endocrinol Diabetes Metab Case Rep. 2016;2016.

  31. Lau SL, Tsang VH. A case of hyperglycaemia in a young woman using an insulin pump.. Endocrinology Today. 2016;5(2):5.

  32. Fraser S, Go C, Aniss A, Sidhu S, Delbridge L, Learoyd D, Clifton-Bligh R, Tacon L, Tsang V, Robinson B, Gill AJ, Sywak M BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer. World journal of surgery. 2016;40(7):1618-24.

  33. Tsang VHM Robinson B. Update on thyorid cancer. Australian Thyroid Foundation Newsletter. 2015.

  34. Tsang VH, Tacon LJ, Learoyd DL, Robinson BG. Pheochromocytomas in Multiple Endocrine Neoplasia Type 2. Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer. 2015;204:157-78.

  35. Luttrell M, Chamption B, Tsang V. Managing an acute case of Addison's disease. Endocrinology Today. 2015;4(4):4.

  36. Kozusko K, Tsang VH, Bottomley W, Cho YH, Gandotra S, Mimmack M, et al. Clinical and molecular characterization of a novel PLIN1 frameshift mutation identified in patients with familial partial lipodystrophy. Diabetes. 2015;64(1):299-310.

  37. Kim E, Rath EM, Tsang VH, Duff AP, Robinson BG, Church WB, et al. Structural and functional consequences of succinate dehydrogenase subunit B mutations. Endocrine-related cancer. 2015;22(3):387-97.

  38. Gupta A, Champion B, Tsang VH. Managing an elderly woman with Graves' disease. Endocrinology Today. 2015;5(1):29-32.

  39. Tsang VH, Dwight T, Benn DE, Meyer-Rochow GY, Gill AJ, Sywak M, et al. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours. Endocrine-related cancer. 2014;21(3):415-26.

  40. Tsang V, Campbell, L. Catecho-Strophic Diabetic Ketoacidosis. The Best of Grand Rounds. Wiley-Blackwell Publishing Award for Clinical Excellence. Internal Medicine Journal. 2010;40(Suppl. 1):1.